Current state of CAR-T therapy for T-cell malignancies

Chimeric antigen receptor T-cell (CAR-T) therapy has been approved for relapsed/refractory B-cell lymphomas and greatly improves disease outcomes. The impressive success has inspired the application of this approach to other types of tumors. The relapsed/refractory T-cell malignancies are characteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Liangkui, Zhou, Xuan, Zhou, Lijuan, Liang, Zhao, Yang, Jilong, Tu, Sanfang, Li, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Recent Advances in Immunotherapy for Lymphoma and Multiple Myeloma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806442/
https://www.ncbi.nlm.nih.gov/pubmed/36601636
http://dx.doi.org/10.1177/20406207221143025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806442/
https://www.ncbi.nlm.nih.gov/pubmed/36601636
http://dx.doi.org/10.1177/20406207221143025

Ejemplares similares